RVTY Revvity
Data as of close
Healthcare · Laboratory Analytical Instruments
Revvity (RVTY) is a healthcare company in the Laboratory Analytical Instruments industry, with a market capitalization of $16.9 billion. Shares last traded at $151.70, 10.2% below their 52-week high. Over the past year the stock is up 66.7%. RVTY trades at a price-to-earnings ratio of 71.26, above the Laboratory Analytical Instruments median of 38.26. Net profit margin is 8.2%, above the peer median of 1.9%. Revenue grew 3.7% year over year. The shares yield 0.2% in dividends.
* P/E (TTM) = market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year — the same basis as the peer table and the screener, so it can differ from price ÷ EPS.
Performance
Chart
Full chart →Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.
Technicals
Financials
Trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year; revenue is the fiscal-year figure where quarterly revenue covers under half of it (typical for banks, insurers and REITs), and margins are taken on it; latest reported period ends 2026-07-05. Source: SEC EDGAR/XBRL.
RVTY Dividend History
| Fiscal year end | Total dividends paid | Per share* | Payout ratio |
|---|---|---|---|
| 2025-12-28 | $33M | $0.28 | 14% |
| 2024-12-29 | $34M | $0.28 | 13% |
| 2023-12-31 | $35M | $0.28 | 5% |
| 2023-01-01 | $35M | $0.28 | 6% |
| 2022-01-02 | $32M | $0.28 | 3% |
| 2021-01-03 | $31M | $0.28 | 4% |
| 2019-12-29 | $31M | $0.28 | 14% |
| 2018-12-30 | $31M | $0.28 | 13% |
| 2017-12-31 | $31M | $0.28 | 11% |
| 2017-01-01 | $31M | $0.28 | 13% |
| 2016-01-03 | $32M | $0.28 | 15% |
| 2014-12-28 | $32M | $0.28 | 20% |
*Per share derived as total dividends paid ÷ weighted diluted shares (SEC EDGAR/XBRL annual cash-flow facts). Reported history — not a forecast of future dividends.
Compare payers on the highest-dividend-yield screener.
Recent earnings
| Period | EPS (diluted) | Reported |
|---|---|---|
| Q2 2026 | $0.47 | 2026-08-11 |
| Q1 2026 | $0.36 | 2026-05-12 |
| Q4 2025 (derived) | $0.86 | 2026-02-24 |
| FY 2025 | $2.07 | 2026-02-24 |
| Q3 2025 | $0.40 | 2025-11-04 |
| Q2 2025 | $0.46 | 2025-08-05 |
Q4 marked "derived" = fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive, so it can differ by a cent or two from the issuer's own Q4.
Laboratory Analytical Instruments peers
RVTY vs 14 industry peers (Laboratory Analytical Instruments), by market cap. Data as of close
| A | Agilent Technologies | $48.5B | 33.68 | 6.58 | 19.5% | -1.62% |
| WAT | Waters Corporation | $44.2B | 68.71 | 9.51 | 13.8% | -2.86% |
| ILMN | Illumina, Inc. | $34.2B | 38.26 | 7.55 | 19.7% | -4.10% |
| MTD | Mettler Toledo | $33.6B | 37.14 | 8.14 | 21.9% | +0.17% |
| RVTY | Revvity | $16.9B | 71.26 | 5.81 | 8.2% | -3.38% |
| AVTR | Avantor, Inc. | $10.6B | 31.35 | 1.59 | 5.1% | -2.86% |
| BIO | Bio-Rad Laboratories, Inc. | $9.8B | 44.03 | 3.78 | 8.6% | -1.57% |
| BRKR | Bruker Corp | $8.5B | — | 2.42 | -2.0% | -2.48% |
| TXG | 10x Genomics, Inc. | $8.0B | — | 13.01 | -12.2% | -12.14% |
| ALMR | Alamar Biosciences, Inc. | $2.0B | — | — | — | -5.48% |
| CTKB | Cytek Biosciences, Inc. | $751M | — | 3.63 | -32.2% | -5.56% |
| PACB | Pacific Biosciences Of California, Inc. | $727M | — | — | — | -10.34% |
| MASS | 908 Devices Inc. | $421M | — | 6.92 | -57.0% | -9.26% |
| NAUT | Nautilus Biotechnology, Inc. | $302M | — | — | — | -13.50% |
Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.